IP Library Granted Patent US 11,723,853
Granted Patent B2
US 11,723,853 · App. 17/224,347 · Granted Aug 15, 2023

Composition

Inventor: John Hodgkinson (Surrey, GB)
Assignee: BLOCK DRUG COMPANY INC.
A61K8/463A61K8/40A61K8/442A61K8/466A61Q11/00A61K2800/31A61K2800/596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,723,853
App. No.
17/224,347
Granted
Aug 15, 2023
Kind
B2
Abstract

The invention relates to non-aqueous dentrfrice compositions comprising a surfactant system. The surfactant system consists of a combination of surfactants i.e. a betaine and a taurate surfactant; or a betaine and an alkyl sulphate surfactant; or a betaine, a taurate and an alkyl sulphate surfactant.

Claims (7)

1. A non-aqueous dentifrice composition comprising a non-aqueous carrier wherein the carrier comprises: glycerin in an amount from 50% to 70% by weight of the composition; polyethylene glycol in an amount from 15 to 25% by weight of the composition; a thickening agent consisting of from 0.3% to 1.0% by weight of the composition of a carboxyvinyl polymer and from 5.0% to 15.0% by weight of the composition of a thickening colloidal hydrated silica; and a surfactant system consisting of a first surfactant which is a betaine in an amount from 0.05% to about 4% by weight of the composition and a second surfactant which is a taurate in an amount from 0.5% to 2% by weight of the composition.

2. A composition according to claim 1 wherein the taurate is sodium methyl cocyl taurate.

3. A composition according to claim 1 wherein the dentifrice additive comprises a bioactive glass.

4. A composition according to claim 3 wherein the bioactive glass includes about 45% by weight silicon dioxide, about 24.5% by weight sodium oxide, about 6% by weight phosphorus oxide, and about 24.5% by weight calcium oxide.

5. A composition according to claim 3 wherein the bioactive glass is present in an amount from 1 to 20% by weight of the composition.

6. A composition according to claim 1 comprising an oral care active agent selected from a fluoride source, a desensitizing agent, an anti-calculus agent, an anti-erosion agent, an antimicrobial agent, an anti-plaque agent, a whitening agent, an oral malodour agent or a mixture of at least two thereof.

7. A composition according to claim 6 wherein the fluoride source is sodium monofluorophosphate, stannous fluoride, or an amine fluoride in an amount to provide from 25 to 3500 pm of fluoride ions, preferably from 100 to 1500 ppm.

Assignments (5)
CHANGE OF NAME Recorded Mar 1, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066713/0558 →
CHANGE OF NAME Recorded Feb 28, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066701/0387 →
MERGER Recorded Sep 11, 2023
From: BLOCK DRUG COMPANY, INC.
To: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
Reel/Frame 064855/0839 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2023
From: HODGKINSON, JOHN
To: GLAXO GROUP LIMITED
Reel/Frame 064073/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2023
From: GLAXO GROUP LIMITED
To: BLOCK DRUG COMPANY INC.
Reel/Frame 064073/0561 →